Vanguard Group Inc. Lowers Holdings in LivaNova PLC $LIVN

Key Points

• Vanguard Group Inc. trimmed its LivaNova stake by 6.4% in Q3, selling 157,696 shares to hold 2,297,239 shares (about 4.21% ownership) valued at roughly $120.33 million.
• Analysts are broadly positive — seven Buys, two Holds and one Sell result in a consensus Moderate Buy rating with a $74.78 consensus price target, and several firms (Piper Sandler, Needham, KeyCorp) recently raised targets into the $72–$85 range.
• LivaNova beat quarterly expectations with $0.86 EPS vs. $0.80 and $360.9M revenue (up 12.2% YoY), and issued FY2026 EPS guidance of $4.15–$4.25 while analysts forecast about $2.85 EPS for the current fiscal year.

Vanguard Group Inc. reduced its stake in shares of LivaNova PLC (NASDAQ:LIVN - Free Report) by 6.4% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,297,239 shares of the company's stock after selling 157,696 shares during the quarter. Vanguard Group Inc. owned about 4.21% of LivaNova worth $120,329,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also recently modified their holdings of the company. State of Wyoming purchased a new position in LivaNova during the second quarter valued at $31,000. EverSource Wealth Advisors LLC boosted its holdings in shares of LivaNova by 998.4% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 703 shares of the company's stock valued at $32,000 after purchasing an additional 639 shares during the last quarter. UMB Bank n.a. boosted its holdings in shares of LivaNova by 63.0% during the 3rd quarter. UMB Bank n.a. now owns 792 shares of the company's stock valued at $41,000 after purchasing an additional 306 shares during the last quarter. Bayforest Capital Ltd grew its position in shares of LivaNova by 44.8% during the third quarter. Bayforest Capital Ltd now owns 918 shares of the company's stock valued at $48,000 after purchasing an additional 284 shares in the last quarter. Finally, GAMMA Investing LLC increased its holdings in shares of LivaNova by 90.8% in the third quarter. GAMMA Investing LLC now owns 1,202 shares of the company's stock worth $63,000 after purchasing an additional 572 shares during the last quarter. Hedge funds and other institutional investors own 97.64% of the company's stock.

Analyst Upgrades and Downgrades

Several research firms have weighed in on LIVN. Piper Sandler restated an "overweight" rating and set a $85.00 price target on shares of LivaNova in a report on Thursday, February 19th. Needham & Company LLC boosted their price target on shares of LivaNova from $64.00 to $81.00 and gave the stock a "buy" rating in a research report on Wednesday, February 25th. Wall Street Zen raised shares of LivaNova from a "buy" rating to a "strong-buy" rating in a research note on Saturday, December 20th. KeyCorp began coverage on LivaNova in a research note on Friday, December 19th. They issued an "overweight" rating and a $81.00 price objective for the company. Finally, Mizuho raised their target price on shares of LivaNova from $70.00 to $72.00 and gave the stock an "outperform" rating in a report on Wednesday, December 17th. Seven investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $74.78.

LivaNova Price Performance

Shares of LIVN stock opened at $65.26 on Thursday. LivaNova PLC has a twelve month low of $32.48 and a twelve month high of $71.92. The company has a current ratio of 1.36, a quick ratio of 1.16 and a debt-to-equity ratio of 0.29. The stock has a fifty day simple moving average of $65.03 and a two-hundred day simple moving average of $59.40. The stock has a market capitalization of $3.57 billion, a price-to-earnings ratio of -14.63 and a beta of 0.92.

LivaNova (NASDAQ:LIVN - Get Free Report) last announced its quarterly earnings results on Wednesday, February 25th. The company reported $0.86 EPS for the quarter, beating the consensus estimate of $0.80 by $0.06. LivaNova had a positive return on equity of 16.54% and a negative net margin of 17.46%.The firm had revenue of $360.86 million for the quarter, compared to analyst estimates of $354.31 million. During the same quarter last year, the firm posted $0.81 earnings per share. The business's revenue for the quarter was up 12.2% on a year-over-year basis. LivaNova has set its FY 2026 guidance at 4.150-4.250 EPS. On average, analysts predict that LivaNova PLC will post 2.85 EPS for the current fiscal year.

About LivaNova

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company's primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.